Advancements in Bronchopulmonary Dysplasia Treatment: A Look into the 2024 Pipeline
The 2024 Bronchopulmonary Dysplasia (BPD) pipeline showcases significant progress with over 12 companies developing therapies. Key developments include Airway Therapeutics, Inc.'s Phase 3 trial for zelpultide alfa and Chiesi Farmaceutici SpA's collaboration with Oak Hill Bio on OHB-607. These efforts aim to address the unmet needs in BPD treatment, particularly for preterm infants.
© Copyright 2025. All Rights Reserved by MedPath